Log in

Paris Olympics weightlifting medalist Andreev banned 4 years for doping with anabolic steroid

LAUSANNE, Switzerland (AP) — Olympic weightlifting bronze medalist Bozhidar Dimitrov Andreev was banned Friday for doping with an anabolic steroid and will miss the 2028 Los Angeles Summer Games.

The 29-year-old Bulgarian tested positive last year for mesterolone and was banned for four years to November 2029, the International Testing Agency said.

“Mesterolone is known for its potent androgenic properties by increasing testosterone levels and enhancing male sexual characteristics,” the ITA said in a statement.

You must be a member to read this story.

Join our family of readers starting at $5 for your first month and support local, unbiased journalism.


Already have an account? Log in to continue.

Otherwise, follow the link below to join.

Please log in to continue

Log in
I am anchor

Paris Olympics weightlifting medalist Andreev banned 4 years for doping with anabolic steroid

Posted

LAUSANNE, Switzerland (AP) — Olympic weightlifting bronze medalist Bozhidar Dimitrov Andreev was banned Friday for doping with an anabolic steroid and will miss the 2028 Los Angeles Summer Games.

The 29-year-old Bulgarian tested positive last year for mesterolone and was banned for four years to November 2029, the International Testing Agency said.

“Mesterolone is known for its potent androgenic properties by increasing testosterone levels and enhancing male sexual characteristics,” the ITA said in a statement.

Andreev took bronze in the 73-kilogram class at the 2024 Paris Olympics and placed fifth in the same event at the Tokyo Olympics held in 2021. His Olympic medal is not affected by the doping conviction.

He can appeal against the ruling at the Court of Arbitration for Sport.

Andreev won the gold medal at the 2014 Youth Olympic Games and was twice a European champion.

___

AP Olympics at https://apnews.com/hub/2024-paris-olympic-games

Share with others


Have an opinion on this story? Click here to send a letter to our editors.

Comments

No comments on this item Please log in to comment by clicking here